ATE350056T1 - Zusammensetzungen, die kälteangepasste pferdeinfluenzaviren enthaltende, für die behandlung von bestehende virusinfektionen des atmungssystems - Google Patents

Zusammensetzungen, die kälteangepasste pferdeinfluenzaviren enthaltende, für die behandlung von bestehende virusinfektionen des atmungssystems

Info

Publication number
ATE350056T1
ATE350056T1 AT01922507T AT01922507T ATE350056T1 AT E350056 T1 ATE350056 T1 AT E350056T1 AT 01922507 T AT01922507 T AT 01922507T AT 01922507 T AT01922507 T AT 01922507T AT E350056 T1 ATE350056 T1 AT E350056T1
Authority
AT
Austria
Prior art keywords
viruses
cold
equine influenza
influenza virus
influenza
Prior art date
Application number
AT01922507T
Other languages
German (de)
English (en)
Inventor
Patricia W Dowling
Julius S Youngner
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of ATE350056T1 publication Critical patent/ATE350056T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16164—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01922507T 2000-04-03 2001-03-21 Zusammensetzungen, die kälteangepasste pferdeinfluenzaviren enthaltende, für die behandlung von bestehende virusinfektionen des atmungssystems ATE350056T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19432500P 2000-04-03 2000-04-03

Publications (1)

Publication Number Publication Date
ATE350056T1 true ATE350056T1 (de) 2007-01-15

Family

ID=22717146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922507T ATE350056T1 (de) 2000-04-03 2001-03-21 Zusammensetzungen, die kälteangepasste pferdeinfluenzaviren enthaltende, für die behandlung von bestehende virusinfektionen des atmungssystems

Country Status (8)

Country Link
US (2) US7029903B2 (enExample)
EP (1) EP1267920B1 (enExample)
JP (1) JP2003528925A (enExample)
AT (1) ATE350056T1 (enExample)
AU (2) AU2001249300B2 (enExample)
CA (1) CA2403979A1 (enExample)
DE (1) DE60125736D1 (enExample)
WO (1) WO2001074386A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
US7572620B2 (en) 2005-01-11 2009-08-11 Wisconsin Alumni Research Foundation H3 equine influenza A virus
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
CN102459578A (zh) 2009-01-30 2012-05-16 俄克拉荷马州大学评议会 基于在北美狗中循环的犬瘟热病毒的免疫原性组合物、疫苗和诊断方法
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
ES2687702T3 (es) * 2010-03-10 2018-10-26 Intervet International B.V. Método para protección contra enfermedad causada por patógenos secundarios
TWI537385B (zh) * 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
CN104411330B (zh) * 2012-05-31 2017-02-22 佐蒂斯有限责任公司 用犬呼吸道冠状病毒进行疫苗接种以针对支气管炎博德特菌感染进行保护
JP6560056B2 (ja) * 2015-08-07 2019-08-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス
JP2018088928A (ja) * 2018-02-13 2018-06-14 ウィスコンシン アルムニ リサーチ ファンデイション Ｈ３型ウマａ型インフルエンザウイルス

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3518347A (en) 1965-05-28 1970-06-30 Inst Microbiologie Et D Hygien Vaccine for equine influenza
US3992522A (en) 1973-01-24 1976-11-16 The United States Of America As Represented By The Department Of Health, Education And Welfare Temperature-sensitive recombinant mutant viruses and a process for producing same
US4683137A (en) 1982-04-16 1987-07-28 Cornell Research Foundation, Inc. Temperature sensitive reassortant viruses and a vaccine against equine influenza
AU558483B2 (en) 1982-04-16 1987-01-29 Cornell Research Foundation Inc. Temperature sensitive reassortant viruses and a vaccine against equine influenza
GB8300467D0 (en) 1983-01-08 1983-02-09 Wellcome Found Equine influenza
US4631191A (en) 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
US4920213A (en) 1985-06-20 1990-04-24 Biotechnology Research Partners, Ltd. Method and compositions useful in preventing equine influenza
US5149531A (en) 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
IL105456A (en) 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
US5690937A (en) 1995-06-05 1997-11-25 Aviron Temperature sensitive clustered changed-to-alanine mutants of influenza virus PB2 gene
US6177082B1 (en) * 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses

Also Published As

Publication number Publication date
US20060121521A1 (en) 2006-06-08
WO2001074386A2 (en) 2001-10-11
US7029903B2 (en) 2006-04-18
WO2001074386A3 (en) 2002-05-23
JP2003528925A (ja) 2003-09-30
EP1267920B1 (en) 2007-01-03
AU2001249300B2 (en) 2006-02-16
AU4930001A (en) 2001-10-15
US20040223980A1 (en) 2004-11-11
CA2403979A1 (en) 2001-10-11
DE60125736D1 (de) 2007-02-15
EP1267920A2 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
DK1105497T3 (da) Koldadapterede hesteinfluenzavira
WO2001060849A3 (en) Cold-adapted equine influenza viruses
TW200730188A (en) Vaccines and methods to treat canine influenza
ATE350056T1 (de) Zusammensetzungen, die kälteangepasste pferdeinfluenzaviren enthaltende, für die behandlung von bestehende virusinfektionen des atmungssystems
MX9700229A (es) Vacuna de polinucleotido para virus de papiloma.
ATE476983T1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen der atemwege
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
CO5611162A2 (es) Metodos para prevenir enfermedades reproductivas en el ganado vacuno
BR0015398A (pt) Vacinas para mycoplasma bovis e processos de uso
Yousaf et al. Crimean-Congo hemorrhagic fever (CCHF) in Pakistan: the" Bell" is ringing silently
CL2022002412A1 (es) Vacuna
Bray Highly pathogenic RNA viral infections: challenges for antiviral research
ATE298568T1 (de) Albumin-bindende verbindungen die die nichtenzymatische glycosylierung verhindern und die zur behandlung von glycosylierungsbedingten erkrankungen verwendet werden können
Ramanoon et al. Outbreaks of foot-and-mouth disease in Peninsular Malaysia from 2001 to 2007
BR0209251A (pt) Vacina contra vìrus da febre aftosa
JP2003528925A5 (enExample)
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
Dowling et al. Cold-adapted equine influenza viruses
Cintra et al. Safety, immunogenicity and efficacy of influenza vaccine in children
Warfield et al. Filovirus infections
Thomson et al. Foot and Mouth Disease in Southern Africa: Re-evaluation of the approach to control
NO20014372D0 (no) Isolering og delvis karakterisering av en ny antiprokferativ komponent fra humane leukocytter
Iqbal MYTHS AND MYSTERIES ABOUT COVID-19: LESSONS FOR PAKISTAN
ATE373675T1 (de) Impfstoff gegen pferdearteritisvirus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties